)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Matinas BioPharma
Matinas BioPharma (MTNB) investor relations material
Matinas BioPharma Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary8 May, 2026
Executive summary
Clinical-stage biopharma focused on lipid nanocrystal (LNC) platform, seeking partners to monetize MAT2203 and conserve cash while evaluating strategic options.
Net loss for Q1 2026 was $1.92M, up from $1.66M in Q1 2025; accumulated deficit reached $212.7M as of March 31, 2026.
Substantial doubt exists about ability to continue as a going concern due to insufficient cash to fund operations for the next 12 months.
Financial highlights
Cash and cash equivalents at March 31, 2026 were $2.4M, down from $4.0M at year-end 2025.
Total assets decreased to $5.87M from $7.21M at December 31, 2025.
Stockholders’ equity declined to $3.02M from $4.83M at year-end 2025.
No revenue reported; operating expenses for Q1 2026 were $1.94M, flat year-over-year.
Net cash used in operating activities was $1.60M for Q1 2026, compared to $2.01M in Q1 2025.
Outlook and guidance
Operating expenses expected to remain lower in the near term until a partnership or transaction is secured.
Research and development expenses will increase if additional clinical studies are initiated.
Company expects to continue incurring substantial losses for the foreseeable future.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Matinas BioPharma
- Net loss fell to $10.3M in 2025, but cash runway is short without new funding or a MAT2203 deal.MTNB
Q4 202531 Mar 2026 - Oral MAT2203 could transform antifungal therapy by offering safer, more flexible treatment.MTNBFireside Chat3 Feb 2026
- MAT2203 licensing advances, net loss narrows, but cash shortfall raises going concern doubts.MTNBQ2 20241 Feb 2026
- Registering 16.9M shares for resale post-private placement, with ongoing strategic and financial risks.MTNBRegistration Filing16 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Proxy seeks approval for director elections, compensation, reverse split, share increase, and new equity plan.MTNBProxy Filing2 Dec 2025
- Approval sought for major stock issuance, auditor ratification, and potential meeting adjournment.MTNBProxy Filing2 Dec 2025
- Vote on major stock issuance, auditor ratification, and board changes at April 2025 virtual meeting.MTNBProxy Filing2 Dec 2025
- Net loss narrowed, cash declined, and going concern risk persists pending new funding.MTNBQ3 202510 Nov 2025
Next Matinas BioPharma earnings date
Q2 202613 Aug, 2026
Matinas BioPharma
Next Matinas BioPharma earnings date
Q2 202613 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage